{"id":9064,"date":"2025-06-23T21:57:11","date_gmt":"2025-06-23T21:57:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/9064\/"},"modified":"2025-06-23T21:57:11","modified_gmt":"2025-06-23T21:57:11","slug":"sarcopenia-market-to-register-sustainable-growth-at-a-cagr-of-8-1-during-the-study-period-2020-2034","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/9064\/","title":{"rendered":"Sarcopenia Market to Register Sustainable Growth at a CAGR of 8.1% During the Study Period (2020-2034)"},"content":{"rendered":"\n

According to DelveInsight, the sarcopenia market size in the 7MM is projected to grow from USD 2.2 billion<\/b> in 2024 at a significant CAGR through 2034. This growth is expected to be driven by the development of emerging therapies targeting various patient segments, including those with liver cirrhosis, obesity, chronic inflammation, and others.<\/p>\n

Sarcopenia\u00a0 Treatment Market\u00a0<\/b><\/p>\n

Since the underlying causes of sarcopenia are not yet fully understood and no universally effective treatment has been established, it is expected that ongoing research will be focused on uncovering its mechanisms and developing more effective therapeutic options. Currently, prevention and sarcopenia treatment strategies largely revolve around lifestyle modifications, reflecting a major gap in available therapies and emphasizing the urgent need for safe and effective medical interventions for those affected by sarcopenia.<\/p>\n

Healthcare providers often recommend adequate protein intake, balanced nutrition, vitamin D supplementation, and, when appropriate, hormone replacement therapy to manage hormonal imbalances and support musculoskeletal health. Besides nutritional strategies, steroid hormones like dehydroepiandrosterone, testosterone, and anabolic steroids have shown some benefit, though their use is limited due to potential side effects.<\/p>\n

At present, there are no approved drugs specifically for sarcopenia, but researchers are actively exploring pharmacological options. Agents such as Selective Androgen Receptor Modulators (SARMs) and myostatin inhibitors<\/b> are being studied for their potential to enhance muscle mass and function. In addition to non-pharmacological approaches, some patients report using a range of medications and medical procedures to address sarcopenia or its associated conditions, including ibutamoren, creatine, fluconazole, interferon, teriparatide, etanercept, and surgeries related to arthritis, cancer, and cardiovascular issues.<\/p>\n

Sarcopenia<\/b>\u00a0Pipeline Therapies and Key Companies<\/b><\/p>\n

The sarcopenia pipeline is advancing with the development of innovative therapies with different mechanisms of action. Leading pharma companies developing therapies for treating sarcopenia include TNF Pharmaceuticals<\/b> (MYMD-1\/Isomyosamine) (TNF-\u03b1 inhibitors), Biophytis <\/b>(Sarconeos) (Proto-oncogene protein c-MAS-1 agonists), and Lipocine <\/b>(LPCN 1148) (androgen receptor agonist).<\/p>\n

Additionally, companies working on early-phase sarcopenia treatment drugs include ImmunoForge <\/b>(Froniglutide) (Glucagon-like peptide-1 (GLP-1) receptor agonist), Keros Therapeutics<\/b> (KER-065) (Target ActRIIB-Fc), BPGbio <\/b>(BPM 31510) (Targets aerobic glycolytic pathway), and others with their candidates in different stages of clinical development. The success of these candidates could diversify the treatment landscape and intensify competition.<\/p>\n

Biophytis <\/b>is advancing the development of Sarconeos (BIO101)<\/b>, an orally administered small molecule targeting neuromuscular disorders. By activating the MAS receptor in muscle cells, Sarconeos promotes biological resilience and helps preserve muscle function in age-related and muscle-wasting conditions. In 2025, Biophytis plans to launch the Phase II OBA trial to evaluate Sarconeos for obesity-related muscle loss, particularly the loss induced by GLP-1 receptor agonists, through a partnership with Blanver and other collaborators.<\/p>\n

Additionally, Biophytis aims to initiate a Phase III trial under its SARA clinical program to confirm the efficacy of Sarconeos in treating sarcopenia.<\/p>\n

MYMD-1<\/b>, developed by TNF Pharmaceuticals,<\/b> is a novel, orally available TNF-\u03b1 inhibitor designed to treat conditions associated with immune-metabolic dysregulation, such as aging, longevity, and autoimmune disorders. A small but statistically significant Phase II trial in 2023 demonstrated its safety and efficacy in treating sarcopenia, characterized by the progressive decline in muscle mass and strength with age. Unlike existing TNF-\u03b1 blockers, MYMD-1 is the first oral therapy in its class, capable of reducing inflammation without the need for injections or infusions. A Phase III trial is currently being planned, and if approved, MYMD-1 could become the first FDA-approved treatment specifically for sarcopenia.<\/p>\n

In January 2025, TNF Pharmaceuticals announced reaching a major safety milestone for Isomyosamine, supporting the expansion of long-term studies across multiple indications. Furthermore, in December 2024, the company presented encouraging top-line results from a Phase IIa trial of MYMD-1 at a major international conference focused on sarcopenia and related conditions.<\/p>\n

LPCN 1148<\/b>, an oral prodrug of bioidentical testosterone developed by Lipocine<\/b>, is being assessed in a Phase II proof-of-concept study in patients with decompensated cirrhosis. The treatment showed improvements in sarcopenia and associated clinical outcomes. LPCN 1148 represents a potential first-in-class therapy with a unique mechanism for managing cirrhosis. A Phase III trial is currently in the planning phase, with clinical studies being the primary way to access this investigational treatment.<\/p>\n

In December 2024, the FDA granted Fast Track Designation<\/b> to LPCN 1148 for treating sarcopenia in decompensated cirrhosis patients. Earlier, in May 2024, Lipocine presented Phase II data from this study at the European Association for the Study of the Liver (EASL) Congress.<\/p>\n

The anticipated launch of these emerging therapies for sarcopenia\u00a0is poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the sarcopenia\u00a0market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n

Discover more about sarcopenia\u00a0drugs\u00a0in development @\u00a0Sarcopenia<\/b>\u00a0Clinical Trials<\/b><\/a><\/p>\n

Recent Developments in the Sarcopenia Market<\/b><\/p>\n